- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04609046
Testando a adição de lenalidomida e nivolumabe ao tratamento usual para linfoma primário do SNC
Ensaio de fase I de indução com metotrexato, rituximabe, lenalidomida e nivolumabe (Nivo-MR2) seguida de manutenção com lenalidomida e nivolumabe no linfoma primário do SNC
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalidomide may stop or slow primary CNS lymphoma by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Methotrexate is frequently combined with other chemotherapy agents to improve response. This study may help increase the understanding of lenalidomide and nivolumab use in primary CNS lymphoma treatment. In addition, it may help researchers see whether the control of CNS lymphoma can be extended by using these study drugs as maintenance (prolonged therapy) after control is achieved with the initial chemotherapy regimen (induction).
Visão geral do estudo
Status
Intervenção / Tratamento
- Medicamento: Lenalidomide
- Biológico: Rituximab
- Procedimento: Magnetic Resonance Imaging
- Procedimento: Echocardiography Test
- Biológico: Nivolumab
- Procedimento: Lumbar Puncture
- Procedimento: Positron Emission Tomography
- Procedimento: Computed Tomography
- Procedimento: Bone Marrow Aspiration and Biopsy
- Medicamento: Methotrexate
- Procedimento: Ultrasound Imaging
Descrição detalhada
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with high dose-methotrexate (HD-MTX) and rituximab, with or without nivolumab, as induction treatment of primary CNS lymphoma.
II. Determine the proportion of patients who are able to stay on maintenance therapy with lenalidomide and/or nivolumab for 6 months after induction treatment of primary CNS lymphoma.
SECONDARY OBJECTIVES:
I. To evaluate the overall response rate (ORR) of the combination of methotrexate, rituximab, lenalidomide, nivolumab.
II. To evaluate the effect of the treatment regimen and lenalidomide / nivolumab maintenance on progression free survival (PFS).
III. To evaluate the effect of the treatment regimen and lenalidomide / nivolumab maintenance on overall survival (OS).
EXPLORATORY OBJECTIVES:
I. To analyze tumor tissue and cerebrospinal fluid (CSF) for gene expression profiles, and to correlate these profiles with treatment outcomes.
II. To determine whether CSF proteome and metabolome are predictors of outcomes (prognostic marker).
III. To assess response to therapy and minimal residual disease via MRI-based metrics and minimal residual disease of blood and CSF.
IV. To evaluate the relationship between neurocognitive deficits and tumor and brain volumetrics, as assessed by magnetic resonance imaging (MRI) and tumor metabolism.
OUTLINE: This is a dose-escalation study of lenalidomide.
INDUCTION: Patients receive rituximab intravenously (IV) on day 1, methotrexate IV over 2 hours or orally (PO) on day 2, lenalidomide PO daily on days 5-9, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy.
MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo magnetic resonance imaging (MRI) throughout the trial, computed tomography (CT) and positron emission tomography (PET)/CT during screening, and lumbar puncture at the end of the 6th cycle of induction, and after 6 months of maintenance. Patients may also undergo bone marrow aspirate and biopsy, testicular ultrasound and/or echocardiogram (ECHO) during screening.
After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for up to 2 years.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Cedars-Sinai Medical Center
-
San Francisco, California, Estados Unidos, 94143
- UCSF Medical Center-Parnassus
-
-
Florida
-
Coral Gables, Florida, Estados Unidos, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Estados Unidos, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Doral, Florida, Estados Unidos, 33166
- UM Sylvester Comprehensive Cancer Center at Doral
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Estados Unidos, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
North Miami, Florida, Estados Unidos, 33181
- University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
-
Plantation, Florida, Estados Unidos, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Iowa
-
Ankeny, Iowa, Estados Unidos, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Carroll, Iowa, Estados Unidos, 51401
- Saint Anthony Regional Hospital
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Estados Unidos, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Estados Unidos, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Estados Unidos, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Waukee, Iowa, Estados Unidos, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Estados Unidos, 50266-7700
- Methodist West Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Estados Unidos, 70808
- Our Lady of the Lake Physician Group
-
-
Maine
-
Portland, Maine, Estados Unidos, 04102
- MaineHealth Maine Medical Center - Portland
-
Scarborough, Maine, Estados Unidos, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Estados Unidos, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Adrian, Michigan, Estados Unidos, 49221
- Hickman Cancer Center
-
Monroe, Michigan, Estados Unidos, 48162
- Toledo Clinic Cancer Centers-Monroe
-
-
Missouri
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Estados Unidos, 63136
- Siteman Cancer Center at Christian Hospital
-
-
New Jersey
-
Summit, New Jersey, Estados Unidos, 07902
- Overlook Hospital
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health/Center for Advanced Medicine
-
Manhasset, New York, Estados Unidos, 11030
- North Shore University Hospital
-
New York, New York, Estados Unidos, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Estados Unidos, 10065
- NYP/Weill Cornell Medical Center
-
Syracuse, New York, Estados Unidos, 13210
- State University of New York Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
Toledo, Ohio, Estados Unidos, 43623
- Toledo Clinic Cancer Centers-Toledo
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute/University of Utah
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Gundersen Lutheran Medical Center
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Histologically proven primary CNS diffuse large b-cell lymphoma confirmed by one of the following:
- Brain biopsy or resection
- Cerebrospinal fluid
- Vitreous fluid
-
No prior organ transplantation to exclude post-transplant lymphoproliferative disorders
-
No prior chemotherapy or radiation therapy for lymphoma
-
No prior allogeneic stem cell transplantation
-
Use of systemic corticosteroids (dexamethasone up to 24 mg/day or equivalent) for disease control or improvement of performance status to be tapered as fast as clinically safe after initiation of therapy is permissible
-
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown and an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, female of childbearing potential (FCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) =< 7 days prior to registration
-
Age >= 18 years
-
Karnofsky performance scale (KPS) >= 40 (>= 50 for patients older than 60 unless related to lymphoma on investigator's opinion)
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault formula
-
Total Bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
-
No evidence of non-Hodgkin's lymphoma (NHL) outside CNS
-
No prior history of NHL
-
No history of autoimmune disorder. Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as Systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease. Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
-
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (except short course of systemic corticosteroids for disease control or improvement of performance status) or other immunosuppressive medications within 14 days prior to registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
-
Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study
-
No prior or concurrent malignancies with exception of surgically cured carcinoma in situ (CIS) of the uterus, carcinoma of the skin without evidence of disease for >= 5 years
-
No concurrent malignancy requiring active therapy
-
No untreated hepatitis C virus (HCV) infection with detectable HCV viral load
-
No untreated chronic hepatitis B virus (HBV) infection with detectable HBV viral load
-
No untreated human immunodeficiency virus (HIV) infection or with detectable viral load or with CD4+T-cell count of less than 500/mm^3
-
No history of HIV infection and evidence of Epstein Barr virus (EBV)-related primary central nervous system lymphoma (PCNSL)
-
Inability to tolerate anticoagulation with acetylsalicylic acid, warfarin, or direct oral anticoagulants
-
No other investigational agent
-
No history of severe hypersensitivity reaction to any monoclonal antibody
-
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to or other agents used in study
-
Sulfonamide drugs, trimethoprim, salicylates, nonsteroidal anti-inflammatory drugs, penicillin, vitamin C, ciprofloxacin, and proton pump inhibitors should be held at least 48 hours prior to methotrexate administration
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Treatment (rituximab, methotrexate, lenalidomide, nivolumab)
INDUCTION: Patients receive rituximab IV on day 1, methotrexate IV over 2 hours or PO on day 2, lenalidomide PO daily on days 5-9, and nivolumab IV over 30 minutes on day 14. (In dose level IV that includes nivolumab, the doses of rituximab for cycles 2-6 may be given on the same day as nivolumab for the previous cycle). Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response, partial response, or stable disease proceed to maintenance therapy. MAINTENANCE: Within 6 weeks after the last dose of lenalidomide in induction therapy, patients receive lenalidomide PO daily on days 1-21, and nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI, CT, PET/CT, lumbar puncture, bone marrow aspirate and biopsy, testicular ultrasound and ECHO. (See Detailed Description) |
Given PO
Outros nomes:
Given IV
Outros nomes:
Undergo MRI
Outros nomes:
Undergo ECHO
Outros nomes:
Given IV
Outros nomes:
Undergo lumbar puncture
Outros nomes:
Undergo PET/CT
Outros nomes:
Undergo CT and PET/CT
Outros nomes:
Undergo bone marrow aspirate and biopsy Given IV or PO
Outros nomes:
Undergo testicular ultrasound
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Maximum tolerated dose
Prazo: During the first 14-day cycle of treatment
|
Defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients). The number and severity of all adverse events will be tabulated and summarized in this patient population both overall and by dose level according to the Common Terminology Criteria for Adverse Events (CTCAE) Cancer Therapy Evaluation Program version 5.0 criteria. The grade 3+ adverse events will also be described and summarized in a similar fashion. This will provide an indication of the level of tolerance for this treatment combination in this patient group. |
During the first 14-day cycle of treatment
|
|
Proportion of evaluable patients who are able to stay on maintenance therapy
Prazo: Up to 6 months
|
The proportion of evaluable patients who meet the criteria for maintenance feasibility, along with the 95% exact binomial confidence interval, will be provided. |
Up to 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall response
Prazo: Up to 5 years
|
Will be estimated by the number of patients with the objective status of complete response, unconfirmed complete response, or partial response divided by the total number of evaluable patients. The overall response rate with an exact binomial 95% confidence interval will be provided and will be analyzed at the end of induction therapy and again after all therapy (induction and maintenance). |
Up to 5 years
|
|
Progression free survival (PFS)
Prazo: Time from start of induction treatment to progression or death due to any cause
|
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier (Kaplan-Meier, 1958). PFS time from start of maintenance therapy will also be reported in a similar fashion as the PFS time starting from induction therapy. |
Time from start of induction treatment to progression or death due to any cause
|
|
Overall Survival (OS)
Prazo: Time from start of induction treatment to death due to any cause
|
The distribution of overall survival will be estimated using the method of Kaplan-Meier (Kaplan-Meier, 1958). OS time from start of maintenance therapy will also be reported in a similar fashion as the OS time starting from induction therapy. |
Time from start of induction treatment to death due to any cause
|
|
Incidence of adverse events
Prazo: Up to 5 years
|
Toxicity will be measured by the CTCAE version 5.0. The maximum grade, frequency, and severity for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration and analyzed descriptively. |
Up to 5 years
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Minimal residual disease (MRD)
Prazo: Up to 5 years
|
Will estimate the proportion of patients with MRD at each time point with 95% confidence intervals. Will also use swimmer plots and other graphical analyses to visualize when MRD is detected/not detected in sequential samples relative to progression of disease. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Alvaro J Alencar, Alliance for Clinical Trials in Oncology
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Técnicas de investigação
- Terapêutica
- Manipulação de amostras
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Perfurações
- Procedimentos cirúrgicos, operatórios
- Técnicas citológicas
- Citodiagnóstico
- Fenômenos físicos
- Ácidos carboxílicos
- Piperidinas
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Técnicas de diagnóstico, cirúrgico
- Técnicas de química, analíticas
- Análise de espectro
- Pterins
- Pteridinas
- Aminopterina
- Anticorpos, monoclonais, derivados de murinos
- Ftalimidas
- Ácidos ftaléticos
- Ácidos, carbocíclicos
- Piperidones
- Isoindoles
- Técnicas de diagnóstico, neurológico
- Radiação
- Radiação, não ionizante
- Ondas ultrassônicas
- Som
- Lenalidomida
- Nivolumabe
- Rituximabe
- Metotrexato
- Biópsia
- Espectroscopia de ressonância magnética
- Punção espinhal
- CT-P10
- Merphos
- Ondas de choque de alta energia
Outros números de identificação do estudo
- NCI-2020-08331
- U10CA180821 (Concessão/Contrato do NIH dos EUA)
- NCI-2020-08331 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- A051901 (Outro identificador: CTEP)
- A051901 (Outro identificador: Alliance for Clinical Trials in Oncology)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .